Piperine, the sharp-tasting compound in black pepper, is taken not for its own effect but to slow the gut and liver processes that break down other substances, so more of each reaches the blood. That same property raises the blood level of medicines with a narrow safe range. Lifespan and cancer claims rest on cell and animal work. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Alanine aminotransferase | 10–26 U/L (men); 10–19 U/L (women) | Liver-cell stress; the marker that moved in the fatty-liver trials |
| Aspartate aminotransferase | 10–26 U/L | Confirms a liver signal and flags muscle as an alternative source |
| High-sensitivity C-reactive protein | Below 1.0 mg/L | Low-grade inflammation; the marker most consistently moved by curcumin with piperine |
| Low-density lipoprotein cholesterol | Below 100 mg/dL; below 70 mg/dL with existing vascular disease | One of the two lipid fractions the pooled analyses disagree about |
| Triglycerides | Below 80 mg/dL | The fraction the largest pooled analysis found responsive |
| Glycated hemoglobin | 4.8–5.3% | Three-month average blood sugar; the glycemic claim is unproven, so it is tracked rather than assumed |
| Trough level of a narrow-margin medication | Carbamazepine 4–12 µg/mL; phenytoin 10–20 µg/mL | Detects the principal risk directly, before it becomes symptomatic |
| International normalized ratio | Indication-specific; commonly 2.0–3.0 | Piperine inhibits CYP2C9, the enzyme that clears warfarin |
Cadence: Any drug level at two weeks after starting and again two weeks after any dose change; liver enzymes and the inflammation marker at eight to twelve weeks; the full panel every six to twelve months thereafter